ACHV Stock Analysis: Buy, Sell, or Hold?
ACHV - Achieve Life Sciences, Inc.
$2.65
-0.24 (-8.30%)
▼
5d:
-33.75%
30d:
-43.97%
90d:
-38.87%
WAIT
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
ACHV is down 33.2% this week, but smart money is accumulating calls. Top strike: $2.5 2026-06-18 with 808 OI. Call ratio: 83% View Scanner →
Strength: 10.0/10
Get Alerted When ACHV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ACHV is down 33.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ACHV is down 33.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ACHV is currently trading at $2.65, which is considered oversold relative to its 30-day fair value range of $3.55 to $4.64.
Technical Outlook: Technically, ACHV is in a downtrend. The price is currently testing key support at $2.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.75 (+456.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACHV is in a downtrend. The price is currently testing key support at $2.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.75 (+456.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$3.55 -
$4.64
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.3%)
- BULLISH: Trading 456.6% below Wall St target ($14.75)
- WARNING: Recommendation downgraded due to -33.8% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$3.55 -
$4.64
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$2.66
Resistance Level
$4.33
Current Trend
Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.55
Wall Street Target
$14.75
(+456.6%)
Share & Embed Analysis
Last updated: March 30, 2026 5:06 AM ET
Data refreshes hourly during market hours. Next update: 6:06 AM
Data refreshes hourly during market hours. Next update: 6:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACHV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 60 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 42 HOLD |
